The results of BRIM-3, a phase III randomised, open-label, multicentre trial comparing BRAF inhibitor vemurafenib with standard chemotherapy (dacarbazine) in previously untreated patients with BRAF V600E-mutated melanoma were presented at the annual meeting of the American Society of Clinical Oncology in Chicago, Illinois.
The updated overall survival (OS) analysis had a 10-month median follow-up on vemurafenib. It looked at 675 patients with previously untreated, unresectable stage IIIC or IV metastatic melanoma who were BRAF V600E-mutation positive and were randomised to vemurafenib or dacarbazine. At 12 months, OS rates were 55% in patients who had received vemurafenib compared to 43% in dacarbazine recipients.
However, NICE has announced in its draft guidance that it is not recommending NHS use of vemurafenib owing to its high costs and uncertainties over its survival benefits.
Chapman PB, Hauschild A, Robert C et al. J Clin Oncol 30, 2012; (suppl; abstr 8502)